By Siddhi Mahatole May 5 (Reuters) - Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the ...

By Siddhi Mahatole May 5 (Reuters) - Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage trial in chronic patients, sending its shares up ...

Among patients with autoimmune hyperthyroidism, those who use cannabis are 1.9 times more likely to develop exophthalmos — eyes that appear to bulge from the face — within 1 year of diagnosis, than ...

Viridian Therapeutics' shares rose after the company said its treatment for thyroid eye disease met its primary endpoint in a recent trial. The stock gained 58% to $22.30 in premarket trading Tuesday.

An injectable monoclonal antibody that targets the insulin-like growth factor I receptor improved proptosis in more than half of people with chronic thyroid eye disease, according to topline results ...

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by ...

New research suggests that progression of thyroid eye disease is not limited to the early disease period, with a number of ...